Goldman Sachs Group Inc Avidity Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 784,704 shares of RNA stock, worth $23.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

784,704

Previous 784,704 -0.0%

Holding current value

$23.7 Million

Previous $23.2 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$27.05 - $35.11 $585,605 - $760,096	21,649 Added 2.84%	784,704 $23.2 Million
Q4 2024 Feb 11, 2025	SELL	$29.08 - $52.5 $3.25 Million - $5.86 Million	-111,692 Reduced 12.77%	763,055 $22.2 Million
Q3 2024 Nov 14, 2024	BUY	$37.21 - $48.14 $12.3 Million - $15.9 Million	330,696 Added 60.78%	874,747 $40.2 Million
Q2 2024 Aug 13, 2024	BUY	$22.73 - $40.85 $653,964 - $1.18 Million	28,771 Added 5.58%	544,051 $22.2 Million
Q1 2024 May 15, 2024	BUY	$9.16 - $25.52 $1.48 Million - $4.12 Million	161,635 Added 45.71%	515,280 $13.1 Million
Q4 2023 Feb 13, 2024	SELL	$4.87 - $9.37 $595,430 - $1.15 Million	-122,265 Reduced 25.69%	353,645 $3.2 Million
Q3 2023 May 14, 2024	BUY	$6.3 - $11.35 $770,269 - $1.39 Million	122,265 Added 34.57%	475,910 $3.04 Million
Q3 2023 Nov 14, 2023	SELL	$6.3 - $11.35 $503,527 - $907,148	-79,925 Reduced 14.38%	475,910 $3.04 Million
Q2 2023 May 14, 2024	SELL	$10.62 - $17.34 $4.86 Million - $7.94 Million	-457,640 Reduced 45.16%	555,835 $6.16 Million
Q2 2023 Aug 14, 2023	SELL	$10.62 - $17.34 $4.86 Million - $7.94 Million	-457,640 Reduced 45.16%	555,835 $6.16 Million
Q1 2023 May 14, 2024	SELL	$15.35 - $25.65 $1.62 Million - $2.7 Million	-105,312 Reduced 9.41%	1,013,475 $15.6 Million
Q1 2023 May 11, 2023	SELL	$15.35 - $25.65 $1.62 Million - $2.7 Million	-105,312 Reduced 9.41%	1,013,475 $15.6 Million
Q4 2022 May 14, 2024	BUY	$10.06 - $22.66 $5.03 Million - $11.3 Million	499,887 Added 80.77%	1,118,787 $24.8 Million
Q4 2022 Feb 13, 2023	BUY	$10.06 - $22.66 $5.03 Million - $11.3 Million	499,887 Added 80.77%	1,118,787 $24.8 Million
Q3 2022 May 14, 2024	BUY	$15.46 - $23.43 $6.73 Million - $10.2 Million	435,617 Added 237.67%	618,900 $10.1 Million
Q3 2022 Nov 10, 2022	BUY	$15.46 - $23.43 $6.73 Million - $10.2 Million	435,617 Added 237.67%	618,900 $10.1 Million
Q2 2022 May 14, 2024	SELL	$11.18 - $20.5 $1.9 Million - $3.49 Million	-170,362 Reduced 48.17%	183,283 $2.66 Million
Q2 2022 Aug 15, 2022	BUY	$11.18 - $20.5 $686,351 - $1.26 Million	61,391 Added 50.37%	183,283 $2.66 Million
Q1 2022 May 16, 2022	BUY	$14.2 - $23.78 $165,557 - $277,251	11,659 Added 10.58%	121,892 $2.25 Million
Q4 2021 Feb 14, 2022	SELL	$20.4 - $28.66 $4.78 Million - $6.71 Million	-234,246 Reduced 68.0%	110,233 $2.62 Million
Q3 2021 Nov 10, 2021	BUY	$18.16 - $25.21 $6.26 Million - $8.68 Million	344,479 New	344,479 $8.48 Million

Others Institutions Holding RNA

# of Institutions

244

Shares Held

116M

Call Options Held

289K

Put Options Held

998K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.58B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Avidity Biosciences, Inc. Transaction History